Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06492122 · ClinicalTrials.gov registry record · Phase 1

Study With [225Ac]Ac-FL-020 in mCRPC Participants

A Phase 1 study of Metastatic Castration-Resistant Prostate Cancer, sponsored by Full-Life Technologies.

Recruiting
Registry status
Phase 1
Development phase
50
Enrollment target
9
Study locations

NCT06492122 is a Phase 1 study of Metastatic Castration-Resistant Prostate Cancer that is actively recruiting participants, run by Full-Life Technologies. The registered enrollment target is 50 participants, below the 197-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (75% lower). The trial reports 9 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06492122, a Phase 1 study of Metastatic Castration-Resistant Prostate Cancer, is actively recruiting participants, sponsored by Full-Life Technologies.

RECRUITING
Registry status
Phase 1
Development phase
50 participants
Enrollment target
9
Study locations

Study Summary

The purpose of this study is to evaluate the safety, therapeutic effect, and pharmacokinetics of \[225Ac\]Ac-FL-020 in participants with metastatic castration-resistant prostate cancer (mCRPC).

Conditions Studied

Metastatic Castration-Resistant Prostate Cancer

Interventions

  • DRUG [225Ac]Ac-FL-020
  • DRUG Blood samples for PK
  • DRUG [111In]In-FL-020
  • PROCEDURE Blood and urine samples collection
  • PROCEDURE SPECT/CT images

Study Locations (9)

Other

  • Princess Alexandra Hospital - Brisbane
  • Genesiscare Murdoch - Murdoch
  • MacQuarie University Clinical Trial Unit - Sydney
  • Beijing Cancer Hospital - Beijing
  • Ankara Üniversitesi Tıp Fakültesi Cebeci Hastanesi Nükleer Tıp Anabilim Dalı - Ankara

California

  • City of Hope Medical Center - Duarte
  • Chao Family Comprehensive Cancer Center - Irvine
  • University of Stanford - Stanford

Virginia

  • University of Virginia Cancer Center - Charlottesville

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2024-08-30
Est. Completion 2026-12
Phase Phase 1

Sponsor

Full-Life Technologies

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06492122

The ClinicalTrials.gov registry entry for NCT06492122 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 197-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (75% lower). The listed sponsor is Full-Life Technologies, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Metastatic Castration-Resistant Prostate Cancer appearing as the primary indexed condition, and to 5 interventions - of which [225Ac]Ac-FL-020 is the first listed.

NCT06492122 reports 9 study locations spanning 3 distinct geographic areas - top geographies include Other, California, Virginia.

Frequently Asked Questions

What is clinical trial NCT06492122 about?

NCT06492122 is a clinical study titled "Study With [225Ac]Ac-FL-020 in mCRPC Participants". The purpose of this study is to evaluate the safety, therapeutic effect, and pharmacokinetics of \[225Ac\]Ac-FL-020 in participants with metastatic castration-resistant prostate cancer (mCRPC).

What is the current status of trial NCT06492122?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2024-08-30. Estimated completion is 2026-12.

What conditions does trial NCT06492122 study?

This clinical trial studies the following conditions: Metastatic Castration-Resistant Prostate Cancer.

What interventions are being tested in trial NCT06492122?

The interventions under investigation include: [225Ac]Ac-FL-020 (DRUG), Blood samples for PK (DRUG), [111In]In-FL-020 (DRUG), Blood and urine samples collection (PROCEDURE), SPECT/CT images (PROCEDURE).

Who is sponsoring clinical trial NCT06492122?

This trial is sponsored by Full-Life Technologies, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06492122 being conducted?

This trial has 9 study locations across California, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Castration-Resistant Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Castration-Resistant Prostate Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.